<DOC>
	<DOCNO>NCT00239928</DOCNO>
	<brief_summary>This study examine safety efficacy pegaptanib sodium Japanese patient wet-type age-related macular degeneration ( AMD ) , benefit treatment want continue treatment completion precede study ( A5751010 ) .</brief_summary>
	<brief_title>Clinical Study Of Pegaptanib Sodium ( EYE001 ) For Wet-Type Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<criteria>After completion precede study ( A5751010 ) Serious heart , kidney and/or liver disease Diabetic retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Long-Term Study For Pegaptanib Sodium In Patients With Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration</keyword>
</DOC>